Caresyntax Secures $180 Million in Series C Funding to Revolutionize Surgical Intelligence

Caresyntax, a pioneering force in surgical intelligence, has successfully raised $180 million in its latest funding round to advance its mission of making surgery safer and smarter. With a robust dedication to integrating AI-powered software, devices, and clinical services, Caresyntax helps healthcare providers optimize surgical outcomes through its enterprise-grade, vendor-neutral platform. This innovative system leverages advanced proprietary software and hardware to aggregate and analyze a comprehensive array of surgical data—from EMR and video to device metrics and clinical performance indicators—ensuring a holistic understanding of the surgical workflow. The newly acquired funds will be strategically utilized to enhance the platform’s capabilities, expand its reach into international markets, and fuel ongoing research and development. By improving surgical workflow processes before, during, and after procedures, Caresyntax not only supports surgical teams in over 3,000 operating rooms worldwide but also plays a critical role in generating actionable insights for medical device companies, insurers, and other stakeholders in the healthcare ecosystem. As Caresyntax continues to innovate, the company is poised to deliver transformational changes in surgical care delivery, ultimately benefiting the millions who undergo surgical procedures each year. Operating out of its headquarters in San Francisco and with a presence in Berlin, Caresyntax is at the forefront of redefining the standards of surgical safety and efficacy. To discover more about their groundbreaking advancements in surgical care, visit www.caresyntax.com.